Corporate Statement

Mallinckrodt Pharmaceuticals is a multibillion dollar specialty pharmaceutical company focused on our mission: Managing Complexity. Improving Lives. We provide medicines to address unmet patient needs, stemming from 150 years of using our unique strengths, experience and expertise to help improve people’s lives. Discover how our rich history of innovation and patient-centered solutions has helped influence our vision for the future.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Overview

News Releases

16 Feb '23
DUBLIN , Feb. 16, 2023 /PRNewswire/ --  Mallinckrodt plc  (NYSE American: MNK), a global specialty pharmaceutical company, today announced that Siggi Olafsson , President and Chief Executive Officer, will present at Cowen's 43 rd Annual Health Care Conference in Boston, MA on Tuesday, March 7, 2023
08 Feb '23
DUBLIN , Feb. 8, 2023 /PRNewswire/ -- Mallinckrodt plc  (NYSE American: MNK), a global specialty pharmaceutical company, today announced that it will report fourth quarter 2022 earnings results for the period ended December 30, 2022, on Tuesday, February 28, 2023 .      A conference call for
go back to the top of the page